Tango Therapeutics Shares Dip on Safety Hurdles in Pancreatic Study

The company’s drug, vopimetostat, is being studied in combination with Revolution Medicines' daraxonrasib to treat specific forms of pancreatic ductal adenocarcinoma and non-small cell lung cancer. Clinical data indicated an 82% objective response rate and a nine-month median progression-free survival rate of 88%. Despite these results, investigators identified three dose-limiting toxicities in two out of four patients at the second dose level. Additionally, 40% of patients at the first dose level experienced Grade 3 treatment-related adverse events.

Chief Executive Malte Peters noted that these findings align with earlier clinical data while providing a more extensive follow-up period. Following discussions with the Food and Drug Administration, Tango Therapeutics plans to launch a registrational Phase 3 trial in the first half of 2027. Peters maintains that PRMT5 inhibition remains a viable backbone for future combination therapies despite the current safety setbacks.